A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of SC411 in Children With Sickle Cell Disease

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of SC411 in Children With Sickle Cell Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Docosahexaenoic acid (Primary) ; Soya oil emulsion
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Acronyms SCOT
  • Sponsors Sancilio & Company
  • Most Recent Events

    • 01 Nov 2017 Primary endpoint has been met. (Change from baseline in the blood cells omega-3 fatty acids index),according to Sancilio Pharmaceuticals media release.
    • 01 Nov 2017 Topline results published in a Sancilio Pharmaceuticals media release.
    • 03 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top